We referred to the recently updated ELN guidelines and classified AML mutation patients into the low, medium and high-risk groups according to the guidelines’ risk stratification criteria, and results showed that Nrf2 was highly expressed in the high-risk group of AML patients with gene mutations, compared with the low-risk and medium-risk groups (P < 0.001, Fig. 2D), suggesting that high expression of Nrf2 might be related to gene mutations in AML patients. This evidence concerns the gene NFE2L2 and acute myeloid leukemia.